stockrowAxoGen, Inc.
AXGN Healthcare Medical Devices
AxoGen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $225.2 million, up 20.2% from fiscal 2024.
- Revenue
- +26.2%
- EPS
- +163.2%
- Free cash flow
- +995.0%
- Total debt
- −73.1%
Quarter to September 2026, against a year earlier
Follow AXGN
Alert me
AxoGen, Inc. (AXGN) Revenue growth
AxoGen, Inc.'s revenue growth over the twelve months to 30 September 2026 was 24.3%, up 4.1 percentage points from fiscal 2025 (20.2%). Over the past ten years it has ranged from 5.24% (fiscal 2020) to 62.5% (fiscal 2015); the current reading is higher than 55% of that period. That is above the Medical Devices industry median of 10.4% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 20.2% | 2.40 |
| FY2024 | 17.8% | 3.07 |
| FY2023 | 14.7% | 5.93 |
| FY2022 | 8.81% | (4.60) |
| FY2021 | 13.4% | 8.17 |
| FY2020 | 5.24% | (21.89) |
| FY2019 | 27.1% | (11.78) |
| FY2018 | 38.9% | (8.08) |
| FY2017 | 47.0% | (3.42) |
| FY2016 | 50.4% | (12.11) |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 26.2% | 3.16 |
| Jun 2026 | 23.1% | (3.50) |
| Mar 2026 | 26.6% | 5.31 |
| Dec 2025 | 21.3% | (2.26) |
| 43 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| ESTA Establishment Labs Holdings Inc. compare | 38.6% |
| TMDX TransMedics Group, Inc. compare | 28.5% |
| AXGN AxoGen, Inc. | 24.3% |
| IRTC iRhythm Holdings, Inc. compare | 21.6% |
| UFPT UFP Technologies, Inc. compare | 8.62% |
| INSP Inspire Medical Systems, Inc. compare | −0.19% |
| ITGR Integer Holdings Corporation compare | −0.31% |
| NEOG Neogen Corporation compare | −0.33% |
| ALMR Alamar Biosciences, Inc. compare | — |
| Medical Devices industry median | 10.4% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on AXGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement